Physician profile
Shanthi Thangam
NPI 1417967423
$5,195.05
in general payments reported to CMS, 2019-2025
18 companies · $584 in 2025
The $584 reported for 2025 was more than what a typical Psychiatry provider received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $666 · 2020: $526 · 2021: $1,142 · 2022: $721 · 2023: $790 · 2024: $767 · 2025: $584.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,811 · Education: $329.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,811.37 |
| Education | $329.48 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $756.33 | 2019-2025 | Austedo Xr, Uzedy, Austedo Xr |
| Takeda Pharmaceuticals U.S.A., INC. | $612.16 | 2019-2023 | Trintellix |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $578.15 | 2021-2025 | Caplyta |
| Lundbeck LLC | $509.32 | 2019-2025 | Rexulti |
| Alkermes, INC. | $497.59 | 2021-2025 | Lybalvi, Aristada |
| Corium, LLC | $357.71 | 2021-2025 | Azstarys |
| Abbvie INC. | $353.11 | 2021-2024 | Vraylar |
| Otsuka America Pharmaceutical, INC. | $345.23 | 2019-2025 | Rexulti |
| Sunovion Pharmaceuticals INC. | $316.96 | 2019-2020 | |
| Allergan, INC. | $160.61 | 2019-2020 | |
| Axsome Therapeutics, INC. | $159.37 | 2022-2023 | Auvelity |
| Tris Pharma INC | $137.15 | 2021-2024 | Dyanavel Xr |
| Neurocrine Biosciences, INC. | $121.64 | 2019-2024 | Ingrezza |
| Eisai INC. | $73.97 | 2020 | |
| Alfasigma USA, INC. | $64.81 | 2020-2021 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $61.11 | 2021-2025 | Invega Trinza, Invega Sustenna |
| Ironshore Pharmaceuticals INC. | $56.09 | 2019-2024 | Jornay Pm |
| Supernus Pharmaceuticals, INC. | $33.74 | 2021-2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Shanthi Thangam listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.